Auna S.A.'s SEC filings document a foreign private issuer operating a healthcare services and health-plan platform in Mexico, Peru and Colombia. Current reports on Form 6-K furnish press releases, IFRS financial statements, operating KPIs, annual Form 20-F availability, and updates on healthcare services in Peru, Colombia and Mexico and Oncosalud Peru.
The filing record also covers capital-structure matters, including senior secured notes and completed debt refinancing, as well as material project and agreement disclosures related to the Torre Trecca public-private partnership. These documents frame Auna's results, leverage, segment activity and corporate reporting obligations under its NYSE-listed issuer structure.
AUNA S.A. director and president Zamora Leon Jesus filed an amended Form 3 showing his existing ownership, not new trades. He indirectly holds 32,029,016 Class B common shares through Enfoca entities and indirectly holds 10,100 Class A common shares through Enfoca Ltd.
He also directly owns 30,710 Class A common shares. In addition, he holds share options over 209,677 Class A common shares at an exercise price of $6.32, plus performance share options over 277,778 shares at $6.32 and 2,217,528 shares at $12.00, all with long-dated expirations and vesting tied to future share-price and time-based conditions.
AUNA S.A. ownership filing: Daniel Kaufman reports beneficial ownership of 1,827,749 Class A Ordinary Shares, representing 6.1% of the class.
The filing cites 30,138,747 Class A Ordinary Shares outstanding as of April 9, 2026 from the issuer's 20-F. Kaufman reports sole voting and dispositive power over the shares.
AUNA S.A. President and director Zamora Leon Jesus bought Class A Common Shares in open-market transactions. He purchased 8,727 Class A shares on May 26, 2026 at a weighted average price of $4.2389 per share and 23,273 Class A shares on May 27, 2026 at a weighted average price of $4.1981 per share, totaling 32,000 shares. After these purchases, he directly owns 62,710 Class A shares.
He is also reported as indirectly owning 32,029,016 Class B common shares through the Enfoca Entities. Each Class B common share is convertible into one Class A common share. The reported prices reflect multiple trades within ranges from $4.17 to $4.24 per share.
Auna S.A. is calling its 2026 Annual General Meeting of shareholders in Luxembourg on June 30, 2026 at 3:00 p.m. CEST. Shareholders are asked to approve 2025 standalone and consolidated financial statements, related audit reports, and the allocation of the 2025 financial result.
The agenda also covers confirming share awards to independent directors, granting discharge to directors and the statutory auditor for the 2025 financial year, reappointing the statutory auditor for 2026, and ratifying director remuneration and certain compensations. Shareholders of record as of May 15, 2026 can vote in person, online, or by proxy, with the board recommending a vote “FOR” all nine proposals.
Auna S.A. reported first-quarter 2026 results with solid revenue growth but weaker profitability. Total revenue rose 13% year over year to S/1,178 million, driven by local-currency growth of 8% in Mexico, 9% in Peru, and 14% in Colombia.
Adjusted EBITDA slipped 2% to S/217 million, and margin narrowed to 18.4%, as Peru absorbed unusually high revenue adjustments and delayed pharmacy rebates while Mexico invested in talent and shifted its service mix. Net income fell to S/9 million from S/38 million, mainly due to a non-cash foreign-exchange loss of S/26 million that reversed a prior-year FX gain.
Cash generation strengthened: operating cash flow rose to S/175 million from S/106 million and organic free cash flow grew 2.6x, helping keep the leverage ratio broadly stable at 3.7x net debt to adjusted LTM EBITDA. Management highlighted rapid oncology and volume growth in Mexico, continued margin discipline at Oncosalud Peru, and expanding risk-sharing contracts in Colombia, and reaffirmed full-year revenue and Adjusted EBITDA guidance.
Auna S.A., a Latin American healthcare company operating in Mexico, Peru and Colombia, has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025 with the SEC.
The report is available on both the SEC’s website and Auna’s investor relations site, and shareholders can request hard copies of the audited financial statements free of charge. As of March 31, 2026, Auna’s network comprised 31 healthcare facilities with 2,333 beds and 1.4 million health plan members.
AUNA, S.A. reported a Schedule 13G/A amendment showing RWC Asset Management LLP beneficially owns 1,520,929 shares, equal to 5.05% of the class. The filing states RWC has sole voting and sole dispositive power over the 1,520,929 shares. The amendment is signed by Mr. Fadi Freiha as Compliance Officer.
Auna S.A., a Luxembourg-based healthcare group operating hospitals and prepaid health plans in Mexico, Peru and Colombia, has filed its Form 20-F annual report prepared under IFRS Accounting Standards, including audited consolidated financial statements for the years ended December 31, 2025, 2024 and 2023.
The report explains extensive use of non-GAAP metrics such as EBITDA, Adjusted EBITDA, Adjusted Net Income and Adjusted Leverage Ratio, alongside medical loss ratio to assess performance, especially in healthcare coverage. It highlights reliance on third-party payers and government-linked insurers, long collection cycles—up to 165 days in Colombia—and competition from both private and public providers.
Auna reports positive working capital of S/177.5 million (US$52.8 million) as of December 31, 2025, but flags significant risks: pressure on reimbursement schemes in Colombia, ongoing large IT and ERP implementations with prior migration issues, intense competition for medical talent and brands, and identified material weaknesses in internal control over financial reporting.
Auna S.A. reported preliminary operating metrics for the first quarter ended March 31, 2026 across its healthcare platforms in Mexico, Peru and Colombia. The data cover emergency treatments, surgeries, days hospitalized, capacity utilization and oncology sessions, plus memberships and protected lives.
In Mexico, 1Q26 emergency treatments were 7,864 thousand and chemotherapies and radiotherapies reached 4,162 sessions. In Peru, total capacity utilization was 76.3% and chemotherapies and radiotherapies totaled 12,718 sessions. In Colombia, capacity utilization was 79.3% and protected lives under risk-sharing agreements were 3,057,763 in 1Q26.
As of March 31, 2026, Auna’s network comprised 31 healthcare facilities with 2,333 beds and 1.4 million health plan members, underscoring its position as a large integrated healthcare platform in Latin America. All figures are preliminary and may change when final first-quarter indicators are released.